Inhibitori angiotenzin konvertirajućeg enzima (ACE-inhibitori) imaju ključnu ulogu u liječnju bolesnika duž čitavog kardiovaskularnog kontinuma, od nekomplicirane arterijske hipertenzije do razvijene koronarne bolesti i bolesti srčanog mišića. Temeljem provedenih randomiziranih kliničkih studija može se zaključiti da uz temeljni antihipertenzivni učinak imaju značajni kardio i vazoprotektivni učinak. Bitno je napomenuti da se unutar klase ACE inhibitora, perindopril upravo ističe sa svojim značajnim učincima na poboljšanje funkcije endotela, zapravo inhbirajući patofiziološki proces od samoga početka. Logična je kombinacija perindoprila s diuretikom – indapamidom s obzirom da je njihov kombinirani učinak aditivan, odnosno rezultira optimalnom kontrolom renin angiotenzin-aldosteron sustava i snažnom antihipertenzivnom reakcijom. Perindopril i ramipril su jasno pokazali redukciju kardiovaskularnog rizika u randomiziranim kliničkim pokusima u skupini bolesnika sa stabilnom anginom pektoris, dočim kvinapril i trandolapril nisu imali navedeni učinak. Od svih kardiovaskularnih lijekova, ACE inhibitori imaju navišu razinu dokaza u smislu prevencije kardiovaskularnih događanja tijekom čitavog spektra kardiovaskularnih bolesti. Krkin perindopril, odnosno fiksna kombinacija perindoprila s indapamidom dostupna je u različitim dozama i pakiranjima što ga čini optimalnim izborom na tržištu.Angiotensin-converting enzyme (ACE) inhibitors play a key role in the treatment of patients along the entire cardiovascular continuum from uncomplicated hypertension to developed coronary artery disease and myocardial disease. Based on the conducted randomized clinical trials, we can conclude that they have a significant cardiac and vasoprotective effect in addition to the basic antihypertensive effect. It is important to note that within the class of ACE inhibitors, perindopril is characterized by its very significant effects on improvement of endothelial function, thereby inhibiting pathophysiological process from the outset. The combination of perindopril with the diuretic – indapamide is logical given that their combined effect is additive, that is, it results in an optimal control of the renin angiotensin-aldosterone system and strong anti-hypertensive reaction. Perindopril and ramipril have clearly demonstrated the reduction of cardiovascular risk in randomized clinical trials in the group of patients with stable angina pectoris, whereas quinapril and trandolapril did not show the above effect. Of all cardiovascular drugs, ACE inhibitors have the highest level of evidence in terms of prevention of cardiovascular events during the entire spectrum of cardiovascular diseases. Krka’s perindopril, or a fixed combination of perindopril with indapamide is available in different dosages and packaging, making it the optimal choice on the market
